Cellectis SA (CLLS)
3.25
-0.05
(-1.52%)
USD |
NASDAQ |
Sep 02, 16:00
3.26
+0.01
(+0.31%)
After-Hours: 20:00
Cellectis Research and Development Expense (Annual) : 75.08M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 75.08M |
| December 31, 2024 | 72.02M |
| December 31, 2023 | 87.65M |
| December 31, 2022 | 97.50M |
| December 31, 2021 | 117.66M |
| December 31, 2020 | 86.95M |
| December 31, 2019 | 92.04M |
| December 31, 2018 | 76.57M |
| December 31, 2017 | 80.05M |
| December 31, 2016 | 78.43M |
| December 31, 2015 | 57.94M |
| December 31, 2014 | 18.92M |
| Date | Value |
|---|---|
| December 31, 2013 | 23.32M |
| December 31, 2012 | 24.42M |
| December 31, 2011 | 17.11M |
| December 31, 2010 | 16.29M |
| December 31, 2009 | 11.08M |
| December 31, 2008 | 0.00 |
| December 31, 2007 | |
| December 31, 2006 | 0.00 |
| December 31, 2005 | 0.00 |
| December 31, 2004 | 0.00 |
| December 31, 2003 | 0.00 |
| December 31, 2002 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| DBV Technologies SA | 107.12M |
| Akari Therapeutics Plc | 2.822M |
| EDAP TMS SA | -- |
| Autolus Therapeutics Plc | 128.59M |
| Evaxion AS | 9.691M |